SHAREHOLDER ALERT: WeissLaw LLP Investigates Fibrocell Science, Inc.

NEW YORK, Oct. 25, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Fibrocell Science, Inc. ("FCSC" or the "Company") FCSC in connection with the proposed acquisition of the Company by Castle Creek Pharmaceuticals, Inc.  Under the terms of the acquisition agreement, FCSC shareholders will receive $3.00 cash for each FCSC share they own. 

If you own FCSC shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

http://www.weisslawllp.com/fibrocell-science-inc/

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

WeissLaw is investigating whether FCSC's Board acted to maximize shareholder value prior to entering into the acquisition agreement.  Notably, the Company's portfolio includes many products and therapies at various stages of clinical trials.  Among these is the promising FCX-007, an investigational late-stage gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa.  FCX-007 offers the potential to address the underlying cause of the disease and is currently in Phase 3 of clinical trials.  If successful, the Company anticipates filing a Biologics License Application filing in 2021.

Given these facts, WeissLaw is concerned whether the proposed acquisition undervalues the Company, and whether all material information related to the proposed acquisition is fully and fairly disclosed. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

SOURCE WeissLaw LLP